FDA/SEC Cooperation On Investor Communications To Be Headed By Taylor
Executive Summary
FDA Associate Commissioner for Regulatory Affairs John Taylor will serve as the liaison with the Securities & Exchange Commission as FDA expands its role in regulating investor communications
You may also be interested in...
Biopure Disclosure Policies To Be Reviewed Under Hemopure SEC Settlement
Biopure must undergo a review of its disclosure, compliance and other securities policies as part of a settlement with the Securities & Exchange Commission over alleged misrepresentations concerning its investigational synthetic blood product Hemopure
Biopure Disclosure Policies To Be Reviewed Under Hemopure SEC Settlement
Biopure must undergo a review of its disclosure, compliance and other securities policies as part of a settlement with the Securities & Exchange Commission over alleged misrepresentations concerning its investigational synthetic blood product Hemopure
Bristol Vanlev Settlement Does Not Include Pre-Marketing Results Disclosure
A settlement over allegations that Bristol-Myers Squibb misled investors about its investigational antihypertensive Vanlev does not establish disclosure guidelines for investigational products